who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

Gilead Sciences (GILD) earnings date & Q3 2026 results

US GAAP · quarter ended 09/30/2026 · released Oct 29

Net income

$2,429M

down 20.4% y/y

Total revenues

$8,300M

up 6.8% y/y

Operating income

$3,462M

up 4.1% y/y

Next report

~ Feb 9

not announced yet

The quarter in brief

Gilead's Q3 2026 revenue rose 7% to $8.3 billion and operating income grew 4.1% to $3,462 million, but net income fell 20.4% to $2,429 million and diluted EPS dropped to $1.94 from $2.43.

Key growth driver: Product sales — the fastest-growing revenue line: $8,289, +13% y/y. · by the Q3 2026 report

All figures in $M.

Sankey diagram of GILD (Gilead Sciences) earnings report for Q3 2026: revenue, costs and profitProduct sales$8,289 · +12.9%Royalty, contract andother revenues$11 · −97.4%Total revenues$8,300 · +6.8%Cost of goodssold$1,571 · +0.1%Research anddevelopmentexpenses$1,608 · +19.5%Acquiredin-processresearch anddevelopmentexpenses$18 · −89.4%Selling, generalandadministrativeexpenses$1,641 · +20.9%Operating income$3,462 · +4.1%41.7% marginInterest expense$269 · +5.1%Other (income)expense, net$130 · vs $569 incomeIncome beforeincome taxes$3,063 · −15.9%Income tax expense$634 · +7.6%20.7% effective rateNet income$2,429 · −20.4%$1.94/sh · 29.3% margin
Sankey diagram of GILD (Gilead Sciences) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Product sales$8,289 · +12.9%
Royalty, contract and other revenues$11 · −97.4%
Total revenues$8,300 · +6.8%
Cost of goods sold$1,571 · +0.1%
Research and development expenses$1,608 · +19.5%
Acquired in-process research and development expenses$18 · −89.4%
Selling, general and administrative expenses$1,641 · +20.9%
Operating income$3,462 · +4.1% · 41.7% margin
Interest expense$269 · +5.1%
Other (income) expense, net$130 · vs $569 income
Income before income taxes$3,063 · −15.9%
Income tax expense$634 · +7.6% · 20.7% effective rate
Net income$2,429 · −20.4% · $1.94/sh · 29.3% margin

Verdict: Gilead's Q3 2026 revenue rose 7% to $8.3 billion and operating income grew 4.1% to $3,462 million, but net income fell 20.4% to $2,429 million and diluted EPS dropped to $1.94 from $2.43.

Gilead raised full-year 2026 product sales guidance to $31,000–$31,300 million from $30,100–$30,400 million, and lowered GAAP diluted EPS guidance to a loss of $(4.40)–$(4.05) from $(3.75)–$(3.40), including about $9.88 per share of acquired IPR&D charges of $12.4 billion. In Q3 2026 the company paid $1.0 billion in dividends, repurchased $370 million of stock and declared a Q4 dividend of $0.82 per share.

Source and notation

Source: Gilead Sciences press release, 8-K EX-99.1 of 10/29/2026 (SEC EDGAR).

Open as an image: Gilead Sciences (GILD), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Gilead Sciences (GILD) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/gild. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/gild"><img src="https://whoreportstoday.com/t/gild/img/gilead-sciences-gild-earnings-sankey.png" alt="Gilead Sciences (GILD) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/gild">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/gild/img/gilead-sciences-gild-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/gild">Gilead Sciences (GILD) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. · Text: Wikipedia, CC BY-SA 4.0, abridged

It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. Market share (US pharma & biotech): ≈4% by TTM revenue.

Heads-up

Company reports

Q3 2026latest breakdownGilead's Q3 2026 revenue rose 7% to $8.3 billion and operating income grew 4.1% to $3,462 million, but net income fell…
Q2 2026The biggest GAAP loss of this earnings season — $10.5B — is pure deal accounting: $11.2B of acquired IPR&D (Arcellx…

Company guidance

Same quarter a year ago (ended December 31, 2025): revenue $7.92B, EPS (GAAP) $1.75

How we calculate

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

GILD earnings history: past report dates

Oct 29, 2026 Thu4:03 pmafter market closeSep 30, 2026$8.3B+7% y/y$1.94−20% y/y
Aug 4, 2026 Tue4:03 pmafter market closeJun 30, 2026$7.8B+10% y/y−$8.45
May 7, 2026 Thu4:03 pmafter market closeMar 31, 2026$7.0B+4% y/y$1.61+55% y/y
Feb 10, 2026 Tue4:02 pmafter market closeDec 31, 2025≈$7.9B+5% y/y≈$1.75+22% y/y
Oct 30, 2025 Thu4:04 pmafter market closeSep 30, 2025$7.8B+3% y/y$2.43+143% y/y
Aug 7, 2025 Thu4:26 pmafter market closeJun 30, 2025$7.1B+2% y/y$1.56+21% y/y
Apr 24, 2025 Thu4:03 pmafter market closeMar 31, 2025$6.7B−0% y/y$1.04
Feb 11, 2025 Tue4:04 pmafter market closeDec 31, 2024≈$7.6B+6% y/y≈$1.43+25% y/y
Nov 6, 2024 Wed4:09 pmafter market closeSep 30, 2024$7.5B+7% y/y$1.00−42% y/y
Aug 8, 2024 Thu4:06 pmafter market closeJun 30, 2024$7.0B+5% y/y$1.29+55% y/y
Apr 25, 2024 Thu4:04 pmafter market closeMar 31, 2024$6.7B+5% y/y−$3.34
Feb 6, 2024 Tue4:04 pmafter market closeDec 31, 2023≈$7.1B−4% y/y≈$1.14−12% y/y
Nov 7, 2023 Tue4:03 pmafter market closeSep 30, 2023$7.1B+0% y/y$1.73+22% y/y
Aug 3, 2023 Thu4:07 pmafter market closeJun 30, 2023$6.6B+5% y/y$0.83−9% y/y
Apr 27, 2023 Thu4:05 pmafter market closeMar 31, 2023$6.4B−4% y/y$0.80
Feb 2, 2023 Thu4:03 pmafter market closeDec 31, 2022≈$7.4B+2% y/y≈$1.30+333% y/y
Show all 16 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Gilead Sciences: 15-year financials

202529,44310,0228,5109,4564,003
202428,7541,66248010,3053,918
202327,1167,6055,6657,4213,809
202227,2817,3304,5928,3443,709
202127,3059,9186,22510,8053,605
202024,6894,0711237,5183,449
201922,4494,2875,3868,3193,222
201822,1278,2005,4557,4762,971
201726,10714,1244,62811,3082,731
201630,39017,63313,50116,2992,455
201532,63922,19318,10820,5031,874
201424,89015,26512,10112,2610
201311,2024,5243,0752,9710
20129,7024,0102,5922,798—
20118,3853,7902,8043,507—

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Gilead Sciences: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
202559,02322,70324,9377,56418,34211,813
202458,99519,33026,7109,99119,17312,004
202362,12522,83324,9876,08516,08511,280
202263,17121,24025,2295,41214,44311,237
202167,95221,06926,6955,33814,77211,610
202068,40718,20231,4025,99715,99611,397
201961,62722,52524,59311,63130,2969,759
201863,67521,38727,32217,94035,83610,605
201770,28320,44233,5427,58831,82311,635
201656,97718,88726,3468,22919,5889,218
201551,71618,53422,17812,85124,7629,890
201434,66415,42612,40410,02717,7145,761
201322,57911,3706,6362,1136,9976,407
201221,2409,3038,2241,8046,1564,238
201117,3036,7397,6069,88413,9192,515

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated11,1526,692+4,460
· incl. D&A (non-cash add-back)depreciation & amortization323280
· incl. stock-based comp (non-cash)share-based compensation683664
Capexpurchases of property & equipment−494−358−136
Free cash flow ≈operating cash flow − capex10,6586,334+4,324
Investing activities, netcapex, acquisitions, securities−8,821−2,958−5,863
· incl. acquisitionsbusinesses net of cash acquired−11,337−461−10,876
Financing activities, netdebt, buybacks, dividends−3,423−6,482+3,059
· incl. buybacksrepurchases of common stock−1,144−1,692+548
· incl. dividends paid−3,108−3,009−99
FX effect on cash−3487−121
Net change in cash−1,126−2,661+1,535
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 30, 2026: $13.0B (25% of total assets). Compare with other S&P 500 companies →

Corporate governance

2/2good

  • Feb 2026Per the cover of its 2025 10-K, one class is registered — GILD common stock; the legal proceedings section contains no shareholder suits or SEC cases (only antitrust and product cases). sec.gov ↗
  • Dec 2025Declared dividend per share has risen every year: $2.72 (2020), $2.92 (2022), $3.16 (2025) (XBRL 10-K). data.sec.gov ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Dec 2025Diluted share count fell 0.6% over 2020→2025; SBC is 3.0% of revenue; buybacks of $1.9B in 2025 (XBRL 10-K). data.sec.gov ↗

Scoring: 2.0, no deductions = 2.0

Share classes
Single class of common stock (10-K cover).
Dilution
Diluted share count 2020→2025 −0.6%; SBC 3.0% of revenue; buybacks of $0.5–1.9B a year.
Disclosure
10-Ks and 10-Qs filed on time, audited US GAAP financials; no deduction.
Dividends
Dividend paid since 2015 and raised every year: $2.72 (2020) → $3.16 (2025); no cuts.
Lawsuits & regulators
The 10-K lists antitrust (HIV drugs) and product suits — industry-wide, no deduction; no shareholder disclosure suits or SEC cases.
Related parties
In the 2026 proxy the board affirmed that directors have no conflicts of interest; no material related-party transactions.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

Gilead Sciences (GILD) earnings: FAQ

When is GILD's next earnings date?

We have not yet seen an announcement of the date from Gilead Sciences (GILD). Based on last year's report on Feb 10, 2026, the next report is expected around Feb 9, 2027.

What time does GILD report earnings?

Gilead Sciences usually reports after market close: its latest results release was filed with the SEC at 4:03 pm ET on Oct 29, 2026.

When did GILD last report earnings?

Gilead Sciences reported Q3 2026 results on Oct 29, 2026.

Where can I find Gilead Sciences's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to GILD's filings; this page breaks the latest report down in a Sankey chart.

What was GILD's net income in Q3 2026?

Gilead Sciences reported net income of $2,429M for Q3 2026 (−20.4% year over year), under US GAAP.

Does Gilead Sciences pay dividends?

Yes. In 2025, Gilead Sciences paid $4,003M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has Gilead Sciences's revenue changed since 2011?

Per its 10-K filings, revenue grew 3.5x: $8,385M in 2011 and $29,443M in 2025. The peak was $32,639M in 2015. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: HCA · Q3 2026 · HSIC · Q3 2026 · HUM · Q2 2026 · IDXX · Q3 2026 · ILMN · Q3 2026 · INCY · Q2 2026 · IQV · Q3 2026 · ISRG · Q3 2026 · JNJ · Q3 2026 · LH · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy